Crucell N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
18 jan 2006 - 08:12
Statutaire naam
Crucell N.V.
Titel
Crucell and Ark Therapeutics Extend PER.C6® Agreement with Commercial License
Bericht
Crucell N.V. (Euronext, NASDAQ: CRXL) announced today that UK-based Ark Therapeutics Group plc (LSE: AKT) has decided to renew its PER.C6® technology licensing agreement. Under the renewed agreement, the parties have negotiated research and also commercial terms for Ark’s development and manufacture of gene-based medicine using Crucell’s PER.C6® technology.
Datum laatste update: 23 december 2025